Zydus Lifesciences' ESG Rating Climbs to 68

Zydus Lifesciences Limited's ESG rating has risen to 68, an improvement from the previous year's score of 66, according to ESGRAIL.

ESGRAIL Assigns New ESG Rating

Zydus Lifesciences Limited announced on April 10, 2026, that ESGRAIL assigned the company an overall ESG rating of 68. This marks an increase from its score of 66 last year.

ESGRAIL, a SEBI-registered ESG rating provider, prepared the report independently. This means the assessment was based on publicly available information and did not involve direct engagement with Zydus Lifesciences.

The company shared this update in compliance with SEBI regulations, providing investors with current information on its environmental, social, and governance performance.

Why the ESG Rating Matters

Environmental, Social, and Governance (ESG) factors are increasingly important for investors, influencing investment decisions and stock valuations. An improving ESG score can indicate better risk management and a commitment to long-term sustainability.

For pharmaceutical companies like Zydus, strong ESG performance is crucial for global market access and securing favorable financing. International buyers and institutional investors are paying close attention to aspects like supply-chain emissions, diversity, and governance. Lenders are also beginning to tie loan costs to ESG performance. This upward trend in its ESG rating could therefore make Zydus more attractive to these stakeholders.

Company's ESG Efforts and Past Ratings

Zydus Lifesciences has shown a commitment to ESG principles through its established ESG Policy, which integrates sustainability into its operations. The company has also expanded its Corporate Social Responsibility (CSR) committee to include ESG, forming a CSR & ESG Committee. This committee features board independence and an ESG professional, highlighting the company's focus on these critical areas.

This is not the first time Zydus has been assessed by rating agencies. Previously, the company received an improved ESG rating of 84/100 from S&P Global for 2025, up from 83/100. It also achieved a CRISIL ESG score of 61 for FY2024-2025, an increase from 59. These earlier ratings reflect ongoing efforts in sustainability reporting and performance improvement.

What Investors Should Note

Shareholders can view this improved ESG score as a positive sign of the company's dedication to sustainability and strong governance.

While the independent nature of the ESGRAIL rating is standard practice, it might encourage Zydus to proactively engage more with rating agencies for future assessments.

This rating further solidifies Zydus's reputation as a company increasingly mindful of its environmental and social impact.

Past Regulatory and Compliance Issues

While the ESG rating has improved, Zydus Lifesciences has faced past regulatory and compliance challenges. In February 2026, the company disclosed penalties of ₹11,800 each from BSE and NSE for technical non-compliance with meeting intimation rules. Additionally, it reported a tax demand penalty of ₹32.8 million in March 2026. A GST audit penalty of ₹10.12 million was also faced in January 2025, which the company stated it intended to appeal.

Industry Context: Peer Comparison

Zydus Lifesciences achieved an ESG rating of 68 from ESGRAIL. In comparison, peer Aurobindo Pharma Limited received an ESG Score of 37 from S&P Global in December 2025. Reports suggest that companies in the Indian pharma sector can sometimes score lower due to a lesser emphasis on environmental and social factors, making Zydus's improved rating stand out within the industry.

Key Rating Figures

• ESGRAIL ESG Rating: 68 for FY26.
• Previous ESGRAIL ESG Rating: 66 for FY25.

Looking Ahead

• Monitor future ESG ratings from ESGRAIL and other agencies like S&P Global and CRISIL to track Zydus's continued progress.
• Observe Zydus Lifesciences' approach to engaging with ESG rating providers.
• Track the company's sustainability initiatives, particularly in environmental stewardship and social responsibility, as outlined in its ESG Policy.
• Assess how this improved ESG standing affects investor sentiment and potential access to favorable financing.
• Keep an eye on the company's financial performance and regulatory compliance for a complete investment view.